# **OncoAdvisorPGx - Validation and Verificatio**

## 1. Validation Strategy
The application was validated using a combination of functional testing and scenario-based case studies. 
The goal was to verify the correctness of variant matching against the PGx rule database, confirm the reproducibility of the generated reports, and ensure proper error handling for special scenarios. 

Validation was performed by manually executing the workflow with five different VCF test files, covering representative cases: 
- files with PGx matches, 
- files with multiple patients, 
- empty files, 
- and files without PGx matches. 

---

## 2. Test Scenarios

| File tested    | Input characteristics                             | Expected output                                | Observed result  | Status |
|----------------|---------------------------------------------------|-----------------------------------------------|------------------|--------|
| example.vcf    | Contains PGx-relevant variants (single patient)   | Matches found, report with recommendations    | Matches found    | Pass   |
| example2.vcf   | Contains different PGx variants (single patient)  | Matches found, different recommendations      | Matches found    | Pass   |
| example3.vcf   | Multi-sample VCF, several patients with matches   | Reports generated per patient with matches    | Reports correct  | Pass   |
| example4.vcf   | Empty file                                        | Empty report without errors                   | Handled correctly| Pass   |
| example5.vcf   | No PGx variants                                   | Report generated with a "no matches" message  | Handled correctly| Pass   |

---

## 3. Acceptance Criteria
- Correct reading and parsing of VCF files. 
- Accurate matching of variants with pharmacogenomic rules from the database. 
- Consistent and reproducible report generation. 
- Robust error handling for empty or non-matching files. 

---

## 4. Results of Validation
- Total cases tested: 5 
- Successful validations: 5/5 
- Observed outcome: the application correctly handled all representative scenarios, including multiple patients, empty inputs, and files without PGx matches. 

---

## 5. Limitations
- Current validation used small test files; scalability with large WES/WGS datasets was not evaluated. 
- Only a subset of pharmacogenomic rules was loaded into the database for validation. 
- Validation was performed outside a clinical environment, using simulated data. 

---

## 6. Future Improvements
- Extend the test suite with large synthetic datasets to measure performance and scalability. 
- Create automated unit and integration tests (e.g., with pytest and CI/CD). 
- Cross-validate results with established pharmacogenomic tools such as PharmCAT.
